Celularity (CELU) Net Income (2019 - 2025)
Celularity (CELU) posted quarterly Net Income of -$24.4 million for Q4 2025, down 83.26% year-over-year from -$145.5 million in Q4 2024, and down 5.56% quarter-over-quarter from -$23.1 million in Q3 2025.
Celularity (CELU) Net Income (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Net Income for 7 consecutive years, with -$24.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income fell 83.26% year-over-year to -$24.4 million; the TTM figure through Dec 2025 stood at -$91.7 million (down 58.42% YoY), while the FY2025 annual figure was -$91.7 million, down 58.43% from the prior year.
- Net Income slipped to -$24.4 million in Q4 2025 per CELU's latest filing, from -$23.1 million in the prior quarter.
- Across five years, Net Income topped out at $49.9 million in Q3 2021 and bottomed at -$93.9 million in Q3 2023.
- Historically, Net Income has averaged -$21.6 million across 5 years, with a median of -$20.9 million in 2024.
- Annual changes were most pronounced in 2022 — Net Income jumped 704.8% — and 2023, when it tumbled 2056.16%.
- Celularity's Net Income stood at -$4.0 million in 2021, then surged by 704.8% to $24.4 million in 2022, then tumbled by 60.93% to $9.5 million in 2023, then plunged by 239.23% to -$13.3 million in 2024, then plunged by 83.26% to -$24.4 million in 2025.
- Business Quant data shows CELU's Net Income at -$24.4 million in Q4 2025, -$23.1 million in Q3 2025, and -$24.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.36 Mn |
| Sep 30, 2025 | -23.08 Mn |
| Jun 30, 2025 | -24.52 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -13.29 Mn |
| Sep 30, 2024 | -16.10 Mn |
| Jun 30, 2024 | -6.49 Mn |
| Mar 31, 2024 | -22.01 Mn |
| Dec 31, 2023 | 9.55 Mn |
| Sep 30, 2023 | -93.88 Mn |
| Jun 30, 2023 | -47.95 Mn |
| Mar 31, 2023 | -64.02 Mn |
| Dec 31, 2022 | 24.43 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 47.83 Mn |
| Mar 31, 2022 | -62.87 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | 49.94 Mn |
| Jun 30, 2021 | -64.52 Mn |
| Mar 31, 2021 | -81.50 Mn |